Loading company…
Shenzhen-based CAR-T drug developer focused on cell and nano antibody drugs, including CAR-T cell and TCR-T products.
Pregene develops CAR-T cell drugs, TCR-T cell injections, CAR-NK drugs, stem cell drugs and PRG1801, with CAR-T indications across hematological tumors, solid tumors and autoimmune diseases. It also fuses cell drugs and nano antibody drugs. Established in 2012, the company received ISO9001 certification, obtained its first clinical trial approval in March 2020 and raised CNY 140 million in Series B funding led by Haier Capital in November 2020. It was listed on the New Three Board in July 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in